Leisure Acquisition Corp. (LACQ) to Combine with Ensysce Biosciences, Inc. in $207M Deal
Leisure Acquisition Corp. (Nasdaq:LACQ) has entered into a definitive combination agreement with clinical stage biopharmaceutical company Ensysce Biosciences, Inc. at an enterprise value of $207 million. The company’s mission and current product pipeline are focused on solving prescription drug abuse – a national priority. The combined entity is expected to trade on the Nasdaq under
Read More